stockrowSanofi
SNY Healthcare Drug Manufacturers General
Sanofi’s revenue for fiscal 2025 (year ended December 2025) was $52.9 billion, up 10.3% from fiscal 2024.
- Revenue
- +13.9%
- EPS
- +8.21%
- Free cash flow
- +99.6%
- Total debt
- −11.2%
Quarter to September 2026, against a year earlier
Follow SNY
Alert me
Sanofi (SNY) EPS (diluted)
Sanofi's EPS (diluted) for fiscal 2025 was $3.62, up 46.0% from $2.48 in fiscal 2024. Over the twelve months to 30 September 2026 it was $2.02. Over the past ten years it has ranged from $1.24 (fiscal 2019) to $5.61 (fiscal 2020); the current reading is higher than 91% of that period. Sanofi ranks 11th of 20 Drug Manufacturers General companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $3.62 | 45.97% |
| FY2024 | $2.48 | 6.44% |
| FY2023 | $2.33 | (33.62%) |
| FY2022 | $3.51 | 19.39% |
| FY2021 | $2.94 | (47.59%) |
| FY2020 | $5.61 | 352.42% |
| FY2019 | $1.24 | (39.22%) |
| FY2018 | $2.04 | 16.89% |
| FY2017 | $1.75 | (14.03%) |
| FY2016 | $2.03 | 12.15% |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $1.45 | 752.94% |
| Jun 2026 | $0.17 | (78.21%) |
| Mar 2026 | $0.78 | — |
| Dec 2025 | −$0.38 | — |
| 39 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| AMGN Amgen Inc. compare | $17.24 |
| AZN AstraZeneca PLC compare | $7.06 |
| NVS Novartis AG compare | $5.24 |
| BMY Bristol Myers Squibb Company compare | $4.51 |
| NVO Novo Nordisk A/S compare | $4.09 |
| GSK GSK PLC Sponsored ADR compare | $2.98 |
| SNY Sanofi | $2.02 |
| PFE Pfizer Inc. compare | $0.71 |
| GILD Gilead Sciences, Inc. compare | −$3.16 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on SNY
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement